1-9 of 9
Antonina Kurtova
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Luciano J. Costa, Fredrik Schjesvold, Rakesh Popat, David Siegel, Saad Z. Usmani, Syed Abbas Ali, Michael P. Chu, Monique A. Hartley-Brown, Nizar J. Bahlis, Albert Oriol, Joaquín Martínez Lopez, Enrique M. Ocio, Karthik Ramasamy, Donna Reece, Emma Searle, Allison Gaudy, Antonina Kurtova, Wen Zhang, Rafael Sarmiento, August Dietrich, Jessica Katz, Michael Pourdehnad, Paul G. Richardson
Journal: Blood
Blood (2024) 144 (Supplement 1): 677.
https://doi.org/10.1182/blood-2024-198403
Published: 2024
Journal Articles

Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

Tracy T. Chow, Nicholas Stong, Saleh Tamim, Chad C. Bjorklund, Antonina Kurtova, Keyur Desai, Joseph T. Hadala, Cynthia Donahue, Phillip Koo, Yue Zhu, Jessica Katz, Anita K. Gandhi, Suzanne Trudel, Nizar J. Bahlis, Paul G. Richardson, Michael Amatangelo
Journal: Blood
Blood (2024) 144 (Supplement 1): 3261.
https://doi.org/10.1182/blood-2024-199019
Published: 2024
Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh
Journal: Blood
Blood (2023) 142 (Supplement 1): 4686.
https://doi.org/10.1182/blood-2023-187748
Published: 2023
Journal Articles

Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing

Bonny Gaffney, Yu Shi, Petrus de Jong, Manuel Sanchez, Celia Fontanillo, Antonia Lopez-Girona, Isaac W. Boss, Antonina Kurtova, Soraya Carrancio, Lilly Wong, Daniel W. Pierce
Journal: Blood
Blood (2022) 140 (Supplement 1): 7108–7109.
https://doi.org/10.1182/blood-2022-157939
Published: 2022
Journal Articles

CD49d Is The Strongest Flow Cytometry-Based Predictor Of Overall Survival In Chronic Lymphocytic Leukemia

Pietro Bulian, MD, Tait D Shanafelt, MD, Chris Fegan, MBBS, Antonella Zucchetto, Lilla Cro, PhD, Holger Nuckel, MD, Luca Baldini, Antonina Kurtova, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Gianluca Gaidano, Giovanni Del Poeta, MD, Chris Pepper, Ph.D., Davide Rossi, Valter Gattei
Journal: Blood
Blood (2013) 122 (21): 672.
https://doi.org/10.1182/blood.V122.21.672.672
Published: 2013
Journal Articles

The Immunophenotype Signature CD49d + CD38 + Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells.

Antonina Kurtova, M.S., Mariela Sivina, Ph.D., Maite P. Quiroga, B.S., William G. Wierda, M.D., Ph.D, Michael J. Keating, MD, Jan A. Burger, M.D., Ph.D.
Journal: Blood
Blood (2009) 114 (22): 356.
https://doi.org/10.1182/blood.V114.22.356.356
Published: 2009
Journal Articles

Migratory Activity and Stromal Cell Adhesion of Mantle Cell Lymphoma Cells Can Be Diminished by Blocking of VLA-4 and CXCR4 Receptors

Antonina Kurtova, MS, Archie Tamayo, Richard J. Ford, Jr., MD, PhD, Jan A. Burger, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2825.
https://doi.org/10.1182/blood.V112.11.2825.2825
Published: 2008
Journal Articles

Standardizing Co-Culture Conditions Between Chronic Lymphocytic Leukemia Cells and Marrow Stromal Cells: Towards a Reliable and Reproducible System to Assess Cell Adhesion-Mediated Drug Resistance

Antonina Kurtova, MS, Maite P. Quiroga, BS, William G. Wierda, M.D., Ph.D, Michael Keating, MB, BS, Jan A. Burger, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3149.
https://doi.org/10.1182/blood.V112.11.3149.3149
Published: 2008
Journal Articles

Inhibition of BCR Signaling Using the SYK Inhibitor R406 Antagonizes Migratory and Pro-Survival Responses in CLL Cells.

Maite P. Quiroga, BS, Antonina Kurtova, MS, William Wierda, MD, PhD, Michael Keating, MB, BS, Jan A. Burger, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2064.
https://doi.org/10.1182/blood.V112.11.2064.2064
Published: 2008